Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax combined with azacitidine and chemotherapy in previously untreated elderly AML
ChiCTR2100045330Phase 4Recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Overall survival, Complete remission and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100045330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045330.